Product Description
AZD5213 is potent, competitive, rapidly reversible, functional antagonist (inverse agonist) at the human H3 receptor. (Sourced from: https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd5213.html)
Mechanisms of Action: H3 Inverse Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Alzheimer Disease|Cognitive Dysfunction|Rett Syndrome|Tourette Syndrome|Low Back Pain
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
---|---|---|---|---|---|---|---|
D3031C00001 | P2 |
Completed |
Low Back Pain |
2015-05-01 |
2024-06-26 |
Primary Endpoints|Treatments |
|
D3032C00001 | P2 |
Completed |
Tourette Syndrome|Rett Syndrome |
2015-02-01 |
2019-03-19 |
Treatments |
|
D3030C00005 | P2 |
Completed |
Cognitive Dysfunction|Alzheimer Disease |
2013-01-01 |
2019-03-19 |
Treatments |
|
D3030C00004 | P1 |
Completed |
Healthy Volunteers |
2011-10-01 |
2019-03-19 |
Treatments |
|
D3030C00002 | P1 |
Completed |
Healthy Volunteers |
2011-05-01 |
2019-03-19 |
Treatments |
|
D3030C00003 | P1 |
Completed |
Healthy Volunteers |
2011-06-01 |
2019-03-19 |
Treatments |
|
D3030C00001 | P1 |
Completed |
Healthy Volunteers |
2010-12-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
---|